IBA
Manufacturing · Belgium · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Chemin Du Cyclotron 3, Louvain-la-Neuve,...Phone Number
+32 10475811Website
www.iba-worldwide.comRevenue
$684.8 MillionStock Symbol
IBABIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About IBA
IBA Group is a global leader in particle accelerator technology, designing and producing innovative solutions for medical and industrial applications. The company develops equipment for cancer diagnosis and treatment, as well as industrial uses like sterilization of medical devices. With a focus on improving health outcomes, IBA supports hospitals worldwide by providing, maintaining, and upgrading advanced technology to protect, enhance, and save lives.Explore more
IBA Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IBA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at IBA
Product Launch: Get notified when IBA launches new products
Check if IBA has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once IBA has new funding data
IBA, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on IBA recently announced quarterly report
Click to see if IBA had a recent Job posting/layoffs
Check out if IBA is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
IBA is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
IBA is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about IBA.
IBA Tech Stack
A closer look at the technologies used by IBA
See more technologies
Most Recent Scoops
Project
IBA has announced that the Actinium-225 clinical pipeline has grown to more than 40 active trials across several indications, including prostate and neuroendocrine cancers, with three trials having reached Phase III and first results expected from 2028.
Medical Research, Pharmaceuticals, Clinical Operations
Earnings
IBA has reported that IBA Technologies net sales reached EUR 127 million in H1 2026, representing approximately 40% of total group sales, with an adjusted EBIT margin of 6.5%, while the two-year equipment book-to-bill ratio closed at 0.7 reflecting sustained revenue conversion and a slower industrial order intake.
Earnings, Finance, Financial Operations
Earnings
IBA has reported that its Proton Therapy segment achieved an adjusted EBIT of EUR 12.3 million for H1 2026, compared to a loss of EUR 2 million in H1 2025, driven by sustained revenue growth, improved execution, and increased installed base scale, with equipment order intake reaching EUR 312 million.
Earnings, Business Finance, Finance
Earnings
IBA has reported net debt of EUR 81 million at the end of June 2026, up EUR 23 million versus year-end, with a net leverage ratio of 1.14 times adjusted EBITDA, while retaining full access to its committed credit lines.
Business Finance, Finance, Financing & Debt
Earnings
Earnings, Finance
IBA News & Media
IBA joins PFAROS European initiative to advance PFAS destruction for healthcare and pharmaceutical applications
Louvain-la-Neuve, Belgium, 2 September 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its participation in PFAROS, a new European research and innovation initiative launched to address environmental emissions and exposure concerns related to per- and polyfluoroalkyl substances (PFAS) in the pharmaceutical and medical sectors. As part of the project, IBA will co-lead the work on end-of-life and waste-management technIon Beam Applications SA (IOBCF) Q2 2026 Earnings Call Transcript
Ion Beam Applications SA (IOBCF) Q2 2026 Earnings Call August 27, 2026 9:00 AM EDTCompany ParticipantsThomas PevenageOlivier Legrain - CEO, MD & Vice...IBA reports Half Year 2026 results, on track with its improved profitability trajectory
Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued progress towards its profitability improvement trajectory. The period was marked by strong commercial momentum, notably in Proton Therapy and RadioPharma Solutions, as well as the strengthening of IBA’s leadership team and Board to support the Group’s growth and execution of itsIBA Notice of Half Year 2026 Results and Conference Call
HY26 results webcast to take place on Thursday, 27 August 2026 at 3 p.m. CEST
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IBA
Sign Up For FreeTo access detailed company insights
IBA Group is a global leader in particle accelerator technology, designing and producing innovative solutions for medical and industrial applications. The company develops equipment for cancer diagnosis and treatment, as well as industrial uses like sterilization of medical devices. With a focus on improving health outcomes, IBA supports hospitals... Read More
